고요산혈증 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 약제 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,333,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,741,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,260,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

고요산혈증 세계 시장은 2024년 45억 6,000만 달러로 평가되었고, 예측 기간 동안 6.63%의 연평균 성장률(CAGR)로 2030년에는 67억 1,000만 달러에 달할 것으로 예상됩니다.

이 시장은 혈류 내 요산 수치 상승을 특징으로 하는 질환인 고요산혈증의 진단, 치료 및 관리를 중심으로 헬스케어 산업의 역동적이고 진화하는 시장입니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	45억 6,000만 달러
시장 규모 : 2030년	67억 1,000만 달러
CAGR : 2025-2030년	6.63%
급성장 부문	온라인 약국
최대 시장	북미

고요산혈증은 일반적으로 염증성 관절염의 일종인 통풍과 관련이 있으며, 신장 결석 및 심혈관 질환과 같은 다른 질환과도 관련이 있습니다. 최근 몇 가지 주요 촉진요인으로 인해 시장이 크게 성장하고 있습니다.

시장 성장 촉진요인

고요산혈증 유병률 증가

주요 시장 이슈

정기 검진 부족

주요 시장 동향

연구개발(R&:D)에 대한 집중

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 고요산혈증 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(Primary, Secondary)
  • 약제 유형별(Xanthine Oxidase Inhibitors, Nonsteroidal, Anti-Inflammatory Drugs, Corticosteroids, 기타)
  • 투여 경로(경구, 주사)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 유형별
  • 약제 유형별
  • 투여 경로별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 고요산혈증 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 약제 유형별
  • 투여 경로별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 고요산혈증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 고요산혈증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
  • 유형
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 고요산혈증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 고요산혈증 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 고요산혈증 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Arthrosi Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd.
• Urica Therapeutics, Inc
• Zydus Lifesciences
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Hikma Pharmaceuticals Plc
• Mylan N.V.
• AstraZeneca Plc
• Sun Pharmaceutical Industries Ltd

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Hyperuricemia Market was valued at USD 4.56 billion in 2024 and is projected to reach USD 6.71 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.63% during the forecast period. This market represents a dynamic and evolving segment of the healthcare industry, centered on the diagnosis, treatment, and management of hyperuricemia-an ailment marked by elevated uric acid levels in the bloodstream.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.56 Billion
Market Size 2030	USD 6.71 Billion
CAGR 2025-2030	6.63%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Hyperuricemia is commonly associated with gout, a form of inflammatory arthritis, and is also linked to other medical conditions such as kidney stones and cardiovascular disease. The market has experienced notable growth in recent years, propelled by several key drivers.

Key Market Drivers

Rising Prevalence of Hyperuricemia

The increasing global incidence of hyperuricemia serves as a primary growth catalyst for this market. In the United States alone, approximately 38 million people-over 11% of the population-are affected by this condition. Globally, this trend is being fueled by lifestyle factors such as poor dietary habits, physical inactivity, and the growing prevalence of obesity. Notably, in 2022, over one billion individuals worldwide were classified as obese, a condition strongly correlated with elevated uric acid levels.

This rising prevalence has led to heightened demand for both diagnostic tools and therapeutic solutions. Greater public awareness regarding the health risks posed by hyperuricemia has led to increased medical consultations, encouraging early diagnosis and proactive disease management. Furthermore, the aging global population is another significant contributor, as the risk of hyperuricemia rises with age due to diminished renal function. By 2050, individuals aged 60 and above are expected to constitute 22% of the global population, up from 12% in 2015-further intensifying the need for effective management and treatment strategies.

Key Market Challenges

Lack of Routine Screening

One of the critical challenges facing the hyperuricemia market is the limited implementation of routine screening protocols. Hyperuricemia often progresses silently, with few or no symptoms until it leads to more serious complications such as gout, kidney stones, or cardiovascular disorders. Without routine screening, many individuals remain undiagnosed until the condition reaches an advanced stage, resulting in delayed treatment and elevated healthcare costs.

Routine screening not only enables early detection but also provides an opportunity for patient education and preventive intervention through lifestyle modifications-such as improved diet, weight management, and physical activity. Proactive screening is thus a cost-effective strategy to mitigate long-term health complications and reduce the economic burden on healthcare systems.

Key Market Trends

Focus on Research and Development (R&D)

Innovation through research and development has emerged as a central theme in the evolution of the global hyperuricemia market. With strong correlations between hyperuricemia and other debilitating conditions like gout and cardiovascular disease, the need for advanced therapeutic solutions has intensified.

Pharmaceutical companies and academic research institutions are actively pursuing novel treatment approaches, including gene therapy aimed at modifying the genetic pathways that regulate uric acid metabolism. Such innovations could lead to more effective and precisely targeted interventions.

Another emerging trend is the integration of precision medicine into hyperuricemia management. By leveraging patients' genetic, biochemical, and lifestyle data, healthcare providers can deliver highly customized treatment plans that enhance efficacy and reduce adverse effects-ultimately improving patient outcomes.

Ongoing research is also deepening the understanding of the biological mechanisms underlying hyperuricemia and its comorbidities. These insights are aiding in the development of more sophisticated diagnostic tools and next-generation therapeutics, thereby driving sustained market growth.

Key Market Players

• Arthrosi Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd.
• Urica Therapeutics, Inc
• Zydus Lifesciences
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Hikma Pharmaceuticals Plc
• Mylan N.V.
• AstraZeneca Plc
• Sun Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Hyperuricemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hyperuricemia Market, By Type:

• Primary
• Secondary

Hyperuricemia Market, By Drug Type:

• Xanthine Oxidase Inhibitors
• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• Others

Hyperuricemia Market, By Route of Administration:

• Oral
• Injectable

Hyperuricemia Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hyperuricemia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hyperuricemia Market.

Available Customizations:

Global Hyperuricemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hyperuricemia Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Primary, Secondary)
  • 4.2.2. By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others)
  • 4.2.3. By Route of Administration (Oral, Injectable)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Type
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Hyperuricemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Type
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Hyperuricemia Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Type
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Hyperuricemia Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Type
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Hyperuricemia Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Type
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Hyperuricemia Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Type
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Hyperuricemia Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Type
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Hyperuricemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Hyperuricemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Hyperuricemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Hyperuricemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Hyperuricemia Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Type
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Hyperuricemia Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Type
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Hyperuricemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hyperuricemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Hyperuricemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Hyperuricemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Hyperuricemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Hyperuricemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Hyperuricemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Hyperuricemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Hyperuricemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Hyperuricemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Hyperuricemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Hyperuricemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Hyperuricemia Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Arthrosi Therapeutics, Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Dr. Reddy's Laboratories Ltd.
• 14.3. Urica Therapeutics, Inc
• 14.4. Zydus Lifesciences
• 14.5. Takeda Pharmaceutical Company Limited
• 14.6. Novartis AG
• 14.7. Hikma Pharmaceuticals Plc
• 14.8. Mylan N.V.
• 14.9. AstraZeneca Plc
• 14.10.Sun Pharmaceutical Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료